Detalhe da pesquisa
1.
Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial.
J Am Acad Dermatol
; 82(6): 1314-1320, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32007513
2.
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
J Am Acad Dermatol
; 75(3): 494-503.e6, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27417017
3.
A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
J Drugs Dermatol
; 14(12): 1394-9, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26659931
4.
The NK1 receptor antagonist serlopitant for treatment of chronic pruritus.
Expert Opin Investig Drugs
; 28(8): 659-666, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31272246
5.
Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects.
J Allergy Clin Immunol
; 116(4): 780-8, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16210051
6.
The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions.
J Cutan Med Surg
; 7(3): 185-92, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12704534